Clinical Trial Update: Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating lonafarnib with paclitaxel and carboplatin in non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Lonafarnib (lonafarnib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-small-cell Lung, Metastases, Neoplasm | Phase 3 | Status: TERMINATED